Fenofibrate/metformin - Solvay Pharmaceuticals

Drug Profile

Fenofibrate/metformin - Solvay Pharmaceuticals

Alternative Names: Dualtis; LF 23-0121; Synordia

Latest Information Update: 13 Feb 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Sante
  • Developer Solvay Pharmaceuticals
  • Class Antihyperglycaemics; Antihyperlipidaemics; Biguanides; Fibric acid derivatives; Propionates
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Metabolic syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 30 Nov 2008 Discontinued - Phase-III for Metabolic syndrome in European Union (PO)
  • 30 Nov 2008 Discontinued - Phase-III for Type-2 diabetes mellitus in European Union (PO)
  • 08 Dec 2006 Phase-III for Metabolic syndrome in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top